halofuginone has been researched along with Malignant Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chirgwin, JM; Davis, HW; Fournier, PG; Guise, TA; Javelaud, D; Juárez, P; Mauviel, A; McKenna, RC; Mohammad, KS; Niewolna, M; Peng, XH; Yin, JJ | 1 |
| Geffrotin, C; Gerritsen, MJ; Mamor-Cornelissen, I; Rijntjes, J; Ruiter, DJ; van Dijk, MC; van Kempen, LC; van Muijen, GN; Vincent-Naulleau, S | 1 |
2 other study(ies) available for halofuginone and Malignant Melanoma
| Article | Year |
|---|---|
Halofuginone inhibits the establishment and progression of melanoma bone metastases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Disease Progression; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Nude; Piperidines; Quinazolinones; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma.
Topics: Angiogenesis Inhibitors; Animals; Collagen Type I; Humans; Immunohistochemistry; In Situ Hybridization; Melanoma; Neoplasm Invasiveness; Neovascularization, Pathologic; Piperidines; Quinazolinones; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Swine; Swine, Miniature | 2008 |